JP2020527556A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527556A5 JP2020527556A5 JP2020501231A JP2020501231A JP2020527556A5 JP 2020527556 A5 JP2020527556 A5 JP 2020527556A5 JP 2020501231 A JP2020501231 A JP 2020501231A JP 2020501231 A JP2020501231 A JP 2020501231A JP 2020527556 A5 JP2020527556 A5 JP 2020527556A5
- Authority
- JP
- Japan
- Prior art keywords
- mgs
- peptides
- complex
- composition according
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 51
- 239000000203 mixture Substances 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 239000002254 cytotoxic agent Substances 0.000 claims description 26
- 229940127089 cytotoxic agent Drugs 0.000 claims description 26
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 26
- 239000002202 Polyethylene glycol Substances 0.000 claims description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims description 20
- 108010084592 Saporins Proteins 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical group 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 101710167800 Capsid assembly scaffolding protein Proteins 0.000 claims description 4
- 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 claims description 4
- 101710204410 Scaffold protein Proteins 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 238000002512 chemotherapy Methods 0.000 claims description 2
- 238000009169 immunotherapy Methods 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 210000003712 lysosome Anatomy 0.000 claims description 2
- 230000001868 lysosomic effect Effects 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 230000008685 targeting Effects 0.000 claims description 2
- -1 complex Substances 0.000 claims 3
- 210000001367 artery Anatomy 0.000 claims 1
- 230000003068 static effect Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023189168A JP2024012517A (ja) | 2017-07-10 | 2023-11-06 | がん治療用ペプチドサポリン複合体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762530674P | 2017-07-10 | 2017-07-10 | |
| US62/530,674 | 2017-07-10 | ||
| PCT/US2018/041412 WO2019014199A1 (en) | 2017-07-10 | 2018-07-10 | PEPTIDE SAPORIN CONJUGATE FOR THE TREATMENT OF CANCER |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189168A Division JP2024012517A (ja) | 2017-07-10 | 2023-11-06 | がん治療用ペプチドサポリン複合体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020527556A JP2020527556A (ja) | 2020-09-10 |
| JP2020527556A5 true JP2020527556A5 (enExample) | 2021-08-26 |
Family
ID=65002607
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501231A Pending JP2020527556A (ja) | 2017-07-10 | 2018-07-10 | がん治療用ペプチドサポリン複合体 |
| JP2023189168A Pending JP2024012517A (ja) | 2017-07-10 | 2023-11-06 | がん治療用ペプチドサポリン複合体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023189168A Pending JP2024012517A (ja) | 2017-07-10 | 2023-11-06 | がん治療用ペプチドサポリン複合体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11738089B2 (enExample) |
| EP (1) | EP3652195A4 (enExample) |
| JP (2) | JP2020527556A (enExample) |
| CN (2) | CN118240025A (enExample) |
| AU (2) | AU2018301651B2 (enExample) |
| WO (1) | WO2019014199A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11738089B2 (en) | 2017-07-10 | 2023-08-29 | Sri International | Peptide saporin conjugate for the treatment of cancer |
| US20240024495A1 (en) * | 2017-07-10 | 2024-01-25 | Sri International | A peptide saporin conjugate for the treatment of cancer |
| CN118221770A (zh) | 2017-07-10 | 2024-06-21 | 斯坦福国际研究院 | 分子导向系统肽及其用途 |
| US20220380764A1 (en) * | 2019-10-01 | 2022-12-01 | Sri International | Molecular guide system peptides and uses thereof |
| CN119031940A (zh) * | 2021-12-21 | 2024-11-26 | 思研（Sri）国际顾问与咨询公司 | 中枢神经系统细胞特异性递送的双重靶向 |
| WO2023170209A1 (en) * | 2022-03-09 | 2023-09-14 | Ospedale San Raffaele Srl | Fusion proteins and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7671010B2 (en) | 2002-08-30 | 2010-03-02 | The Board Of Regents Of The University Of Texas System | Compositions and methods of use of targeting peptides for diagnosis and therapy of human cancer |
| ES2639301T3 (es) | 2003-04-30 | 2017-10-26 | Universität Zürich | Procedimientos de tratamiento de cáncer usando una inmunotoxina |
| EP1718323B1 (en) | 2004-02-20 | 2011-12-07 | The Trustees of The University of Pennsylvania | Binding peptidomimetics and uses of the same |
| EP1867661A1 (en) | 2006-06-12 | 2007-12-19 | Diatos | Compositions and methods for delivering anti-activated ras antibodies into cells |
| WO2009089186A2 (en) * | 2008-01-05 | 2009-07-16 | Sloan-Kettering Institute For Cancer Research | Peptide-conjugated oligonucleotide therapeutic and method of making and using same |
| US8524220B1 (en) * | 2010-02-09 | 2013-09-03 | David Gordon Bermudes | Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria |
| US8362207B2 (en) | 2010-04-16 | 2013-01-29 | Wake Forest University Health Sciences | Multi-level specific targeting of cancer cells with IL-13 |
| EP2476441A1 (en) | 2011-01-13 | 2012-07-18 | Universitat Autònoma De Barcelona | Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells |
| US9062312B2 (en) | 2011-06-21 | 2015-06-23 | Danisco Us Inc. | Fusion peptides comprising multi-functional peptidic solubility tags for efficient production, processing and surface applications |
| EP3677285B1 (en) | 2014-08-04 | 2023-12-13 | Case Western Reserve University | Targeting peptides for detecting prostate cancer |
| US11080595B2 (en) | 2016-11-04 | 2021-08-03 | Salesforce.Com, Inc. | Quasi-recurrent neural network based encoder-decoder model |
| US20180157388A1 (en) | 2016-12-02 | 2018-06-07 | Google Inc. | Emotion expression in virtual environment |
| KR20190099250A (ko) * | 2016-12-21 | 2019-08-26 | 바이엘 악티엔게젤샤프트 | 효소적으로 절단가능한 기를 갖는 세포독성 활성제의 전구약물 |
| CN118221770A (zh) | 2017-07-10 | 2024-06-21 | 斯坦福国际研究院 | 分子导向系统肽及其用途 |
| US11738089B2 (en) | 2017-07-10 | 2023-08-29 | Sri International | Peptide saporin conjugate for the treatment of cancer |
-
2018
- 2018-07-10 US US16/629,803 patent/US11738089B2/en active Active
- 2018-07-10 EP EP18831080.9A patent/EP3652195A4/en active Pending
- 2018-07-10 CN CN202410388873.8A patent/CN118240025A/zh active Pending
- 2018-07-10 WO PCT/US2018/041412 patent/WO2019014199A1/en not_active Ceased
- 2018-07-10 JP JP2020501231A patent/JP2020527556A/ja active Pending
- 2018-07-10 CN CN201880055897.4A patent/CN111417646B/zh active Active
- 2018-07-10 AU AU2018301651A patent/AU2018301651B2/en active Active
-
2023
- 2023-08-17 AU AU2023216858A patent/AU2023216858A1/en active Pending
- 2023-11-06 JP JP2023189168A patent/JP2024012517A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527556A5 (enExample) | ||
| JP6548630B2 (ja) | 特定の細胞型の選択的死滅のための細胞標的化結合領域と志賀毒素ａサブユニット領域とを含む細胞毒性タンパク質 | |
| Li et al. | Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells | |
| Bansal et al. | Interferon gamma peptidomimetic targeted to hepatic stellate cells ameliorates acute and chronic liver fibrosis in vivo | |
| CA3148621A1 (en) | Compositions and methods comprising protease-activated therapeutic agents | |
| EA029831B1 (ru) | Пептид, индуцирующий цитотоксические т-лимфоциты и стимулирующий антиопухолевые иммунные ответы | |
| KR100377506B1 (ko) | 변이된초항원과표적-탐지화합물간의복합체,이복합체를함유하는제약학적조성물및이를이용한치료방법 | |
| HU228185B1 (en) | Modified/chimeric superantigens and their use | |
| JP2010154842A (ja) | Ｅｇｆｒを標的にした新規抗がんキメラペプチド | |
| JP2024012517A5 (enExample) | ||
| US9388213B2 (en) | Polycomb repressive complex 2 (PRC2) inhibitors and uses thereof | |
| EP0511306B1 (en) | Tumor killing effects of enterotoxins and related compounds | |
| JP2020509737A5 (enExample) | ||
| CN103304631A (zh) | 具有抗肿瘤活性的九肽 | |
| AU2019375096B2 (en) | Polypeptides for the treatment of stress, immunoreaction and stroke syndromes | |
| US6660264B1 (en) | Treatment of intracellular infection | |
| Zhuang et al. | Robo4 vaccines induce antibodies that retard tumor growth | |
| Bose et al. | Peptide therapeutics in the management of metastatic cancers | |
| WO2016186445A1 (ko) | 암 세포 표적용 펩타이드 및 이의 용도 | |
| JP2024517871A (ja) | プロテアーゼ活性化治療剤を含む組成物および方法 | |
| Tan et al. | Combination of low‐dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities | |
| JP7608336B2 (ja) | 中枢神経系原発リンパ腫の併用治療 | |
| CN100393356C (zh) | 用于癌症治疗的经修饰的细胞因子 | |
| IL140732A (en) | Synthetic peptides for diagnosis and treatment of antiphospholipid syndrome | |
| WO2005014798A2 (en) | Novel compositions and methods for promoting, inhibiting, and detecting protein entry into cells |